Allon Therapeutics, Inc. Enrolling Patients in Pivotal Davunetide Phase 2/3 Trial

VANCOUVER, BRITISH COLUMBIA--(Marketwire - January 06, 2011) - Allon Therapeutics Inc. (TSX: NPC) announced today that it has initiated a pivotal Phase 2/3 clinical trial to evaluate the Company’s lead neuroprotective drug candidate, davunetide, as a potential treatment for progressive supranuclear palsy (PSP), a rapidly-progressing and fatal degenerative brain disease. On January 4, 2011, the Company announced that the study will be conducted under a Special Protocol Assessment (SPA), granted by the United States Food and Drug Administration (FDA). Enrollment in the study began in the fourth quarter of 2010.

Bruce Morimoto, Allon’s Vice President of Drug Development, said this trial is a critical step forward in executing the Company’s approval strategy for davunetide. “We believe this pivotal trial will generate data in about 2 years, helping form the basis for approval of davunetide in PSP.”

“There is a strong scientific rationale for the development of davunetide in this disease. The extensive preclinical data suggests that davunetide works by reducing the tau pathology which is found in PSP and also present in Alzheimer’s disease as well as other frontotemporal dementias. Our clinical data also confirms that davunetide can have a positive impact on various clinical outcomes,” Morimoto continued.

Matthew Carlyle, Allon’s Chief Financial Officer, commented that Allon is in a strong financial position to execute the pivotal study.

“With the closing of a $10.2 million investment in the fourth quarter, we have the resources available to complete the study as agreed upon in the SPA and are able to move forward aggressively,” Carlyle said.

The pivotal Phase 2/3 double-blinded, placebo controlled trial in PSP will enroll approximately 300 patients randomized 1:1 to receive either placebo or 30 mg of davunetide twice a day for 12 months. The primary outcome measures will be the Progressive Supranuclear Palsy Rating Scale (PSPRS) and the Schwab and England Activities of Daily Living (SEADL) scale. Secondary measures will include Clinical Global Impression (CGI) and brain imaging by magnetic resonance tomography (MRI). Additional exploratory endpoints include cognitive and executive function as well as cerebrospinal fluid (CSF) biomarkers.

This multi-national study is being conducted at premier medical institutions in the United States, Australia, Germany, France, Canada and the United Kingdom. A list of the clinical trial sites can be found at www.clinicaltrials.gov, NCT 01110720. The study Principal Investigator is Adam Boxer, MD, PhD, Associate Professor of Neurology at the University of California San Francisco and Director of the Alzheimer’s disease and frontotemporal dementia clinical trials program at the UCSF Memory and Aging Center.

Allon previously announced that davunetide received orphan drug designation in the United States (January 12, 2010), the European Union (March 17, 2010), Fast Track Status with the FDA (April 6, 2010), and that davunetide met the primary outcome measure of safety and tolerability, with potential trends from secondary efficacy endpoints, in a pilot study of 12 patients suffering PSP and related tau pathology disorders (October 8, 2010).

About PSP

PSP is one of a group of progressive disorders called frontotemporal dementias (FTD) that affect movement, speech, and behavior, and for which there are no approved treatments. Approximately 20,000 and 50,000 persons in the U.S. and EU respectively have PSP.

Approximately half of FTDs, including PSP, are tauopathies, which are pathologies that involve impairment of the tau protein in brain cells. Allon expects that demonstrating efficacy in PSP will define the opportunity to use davunetide in other FTD subtypes that are tauopathies.

PSP is often characterized by progressive difficulty with balance and walking leading to falls, eye movement abnormalities, and cognitive and personality changes. Patients are typically diagnosed when they are between 45 and 75 years of age. PSP is associated with progressive disability and death often three years following diagnosis. The disease is slightly more common in men than women, but there are no known geographical, occupational, or racial patterns.

Davunetide for PSP

Allon has demonstrated a strong scientific and clinical rationale for the potential efficacy of davunetide in PSP. The pathology of PSP and Alzheimer’s is similar in that both diseases involve impairment of the brain protein tau - and davunetide is the most advanced tau therapy in the world.

Research has shown that davunetide reduced tau impairment and preserved memory in mice bred to replicate Alzheimer’s or PSP tau pathology.

In 2008, Allon reported Phase 2a clinical trial results showing that davunetide had a statistically significant positive impact on memory function in patients with amnestic mild cognitive impairment (aMCI), a precursor to Alzheimer’s. The data was presented July 28 and July 30, 2008 to the International Conference on Alzheimer’s Disease and Related Disorders (ICAD 2008).

On December 7, 2009, Allon reported Phase 2a clinical trial results showing that davunetide improved memory function of schizophrenia patients and had a positive impact on the ability of these patients to carry out important activities in their daily lives.

On March 30, 2010, Allon announced top-line results from an imaging study of schizophrenia patients showing that 12 weeks of treatment with davunetide resulted in a statistically significant increase in levels of a biomarker that is an important indicator of brain cell health. Allon said statistically significant (p=0.0170) increased levels of N-acetyl aspartate (NAA) were measured using magnetic resonance spectroscopy in the brains of the schizophrenia patients treated with davunetide. The scientific literature shows that NAA is an informative biomarker because decreased levels of NAA occur in schizophrenia, and in numerous other neurodegenerative conditions such as brain injury, stroke, and Alzheimer’s.

On October 8, 2010, Allon announced that a pilot clinical trial successfully met its primary endpoint of safety and tolerability with davunetide, in patients with progressive supranuclear palsy (PSP) and other types of frontotemporal dementia (FTD) like corticobasal syndrome, and progressive non-fluent aphasia. Despite the small size and short duration of the pilot clinical trial, the investigators also noted a positive trend on a secondary outcome, the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), a cognitive measure of memory, language, and attention.

Davunetide is a fragment of a naturally occurring neuroprotective brain protein known as activity dependent neuroprotective protein (ADNP). Allon’s laboratory and animal studies have shown that davunetide restores the function of structures in the brain - known as microtubules - which are critical to communication between brain cells and the structure of individual cells.

About Allon’s neuroprotective platforms

Allon’s two neuroprotective technology platforms are based on two naturally occurring proteins produced by the brain in response to a range of insults. The platforms are activity-dependent neuroprotective protein (ADNP) and activity-dependent neurotrophic factor (ADNF).

Because the two platforms are based on different proteins, the drugs from each are different molecules with different therapeutic mechanisms and distinct commercial opportunities. Clinical-stage drugs based on davunetide are derived from ADNP, while preclinical stage drug AL-309 is derived from ADNF. Davunetide is focused on Alzheimer’s disease, cognitive impairment in schizophrenia, and frontotemporal dementia. ADNF drug candidate AL-309 is being developed for the treatment of peripheral neuropathies and is administered orally or subcutaneously.

About Allon

Allon Therapeutics Inc. is a clinical-stage biotechnology company developing treatments for major neurodegenerative conditions. Allon’s drug davunetide has demonstrated human efficacy in amnestic mild cognitive impairment, a precursor to Alzheimer’s disease, and cognitive impairment associated with schizophrenia. Allon has Phase 2 human efficacy programs pursuing large underserved markets, such as Alzheimer’s disease and cognitive impairment associated with schizophrenia, and in orphan markets, such as frontotemporal dementias. The Company is listed on the Toronto Stock Exchange under the trading symbol “NPC” (Neuro Protection Company™) and based in Vancouver. For additional information please visit the Company’s website: www.allontherapeutics.com.

Forward Looking Statements

Statements contained herein, other than those which are strictly statements of historical fact may include forward-looking information. Such statements will typically contain words such as “believes”, “may”, “plans”, “will”, “estimate”, “continue”, “anticipates”, “intends”, “expects”, and similar expressions. While forward-looking statements represent management’s outlook based on assumptions that management believes are reasonable, forward-looking statements by their nature are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by them. Such factors include, among others, the inherent uncertainty involved in scientific research and drug development, Allon’s early stage of development, lack of product revenues, its additional capital requirements, the risks associated with successful completion of clinical trials and the long lead-times and high costs associated with obtaining regulatory approval to market any product which Allon may eventually develop. Other risk factors include the limited protections afforded by intellectual property rights, rapid technology and product obsolescence in a highly competitive environment and Allon’s dependence on collaborative partners and contract research organizations. These factors can be reviewed in Allon’s public filings at www. SEDAR.com and should be considered carefully. Readers are cautioned not to place undue reliance on such forward-looking statements.